| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5591762 | BOEHRINGER INGELHEIM | Benzimidazoles useful as angiotensin-11 antagonists |
Jan, 2014
(10 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5591762 | BOEHRINGER INGELHEIM | Benzimidazoles useful as angiotensin-11 antagonists |
Jan, 2014
(10 years ago) | |
| US6358986 | BOEHRINGER INGELHEIM | Polymorphs of telmisartan |
Jan, 2020
(4 years ago) | |
| US7998953 | BOEHRINGER INGELHEIM | Use of inhibitors of the renin-angiotensin system |
Jun, 2020
(3 years ago) | |
| US8003679 | BOEHRINGER INGELHEIM | Use of inhibitors of the renin-angiotensin system |
Oct, 2022
(1 year, 6 months ago) | |
Micardis is owned by Boehringer Ingelheim.
Micardis contains Telmisartan.
Micardis has a total of 5 drug patents out of which 5 drug patents have expired.
Expired drug patents of Micardis are:
- US5591762
- US6358986
- US7998953
- US8003679
- US5591762
Micardis was authorised for market use on 04 April, 2000.
Micardis is available in tablet;oral dosage forms.
Micardis can be used as reduction of cardiac tissue damage associated with myocardial infarction, treatment of hypertension, treatment or prevention of stroke.
The generics of Micardis are possible to be released after 06 October, 2022.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-612) | Oct 16, 2012 |
Drugs and Companies using TELMISARTAN ingredient
Market Authorisation Date: 04 April, 2000
Treatment: Treatment of hypertension; Reduction of cardiac tissue damage associated with myocardial infarction; Treatment or prevention of stroke
Dosage: TABLET;ORAL
MICARDIS family patents
